Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
- Bryn Mawr Hospital — Bryn Mawr, Pennsylvania
- Christiana Care Health System-Concord Health Center — Chadds Ford, Pennsylvania
- Pocono Medical Center — East Stroudsburg, Pennsylvania
Phase 3 Recruiting Network
This phase III trial tests two hypotheses in patients with low-risk and average-risk medulloblastoma. Medulloblastoma is a type of cancer that occurs in the back of the brain. The term, risk, refers to the chance of the cancer coming back …
Sponsor: Children's Oncology Group
NCT ID: NCT05382338
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 3 Recruiting Network
Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT03550391
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Fox Chase Cancer Center Buckingham — Furlong, Pennsylvania
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Geisinger Wyoming Valley/Henry Cancer Center — Wilkes-Barre, Pennsylvania
Phase 3 Recruiting Industry
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) …
Sponsor: Nuvation Bio Inc.
NCT ID: NCT05303519
Sites in Pennsylvania: - Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Pennsylvania: - University of Pennsylvania - Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- Allegheny General Hospital — Pittsburgh, Pennsylvania
- University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 3 Recruiting Industry
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also imper…
Sponsor: CarThera
NCT ID: NCT05902169
Sites in Pennsylvania: - Penn State Health Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 3 Recruiting Industry
This is a Phase 3 prospective, randomized, superiority, open-label, multi-site study. The overview of this study is as follows: * A Screening/Baseline Period of 21 days. During this time, patients will be randomized into a 1:2 allocation o…
Sponsor: GT Medical Technologies, Inc.
NCT ID: NCT07195591
Sites in Pennsylvania: - Allegheny Health Network — Pittsburgh, Pennsylvania
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Pennsylvania: - University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Pennsylvania: - Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
- Geisinger Medical Center — Danville, Pennsylvania
- Penn State Children's Hospital — Hershey, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or hig…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05099003
Sites in Pennsylvania: - Geisinger Medical Center — Danville, Pennsylvania
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Saint Christopher's Hospital for Children — Philadelphia, Pennsylvania
- Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Pennsylvania: - UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…
Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Pennsylvania: - Thomas Jefferson University — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Sponsor: Giselle Sholler
NCT ID: NCT04696029
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania
Phase 2 Recruiting Academic/Other
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes…
Sponsor: University of California, San Francisco
NCT ID: NCT05009992
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting Industry
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Research…
Sponsor: Diakonos Oncology Corporation
NCT ID: NCT06805305
Sites in Pennsylvania: - UPMC Presbyterian Hospital — Pittsburgh, Pennsylvania
Phase 2 Recruiting Industry
This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified …
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT04775485
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any …
Sponsor: Milton S. Hershey Medical Center
NCT ID: NCT06465199
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center and Children's Hospital — Hershey, Pennsylvania
Phase 2 Recruiting Academic/Other
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIP…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05096481
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This is a Phase II open-label study to investigate the safety and efficacy of ACT001 in patients with DIPG and H3K27-altered HGG.
Sponsor: Nationwide Children's Hospital
NCT ID: NCT06838676
Sites in Pennsylvania: - Children's Hospital of Philidelphia — Philidelphia, Pennsylvania
Phase 2 Recruiting Industry
The purpose of this research is to test an investigational device using ultrasound along with an investigational drug to see if it is useful in treating glioblastoma following standard of care therapy surgery and chemoradiation. This study…
Sponsor: Alpheus Medical, Inc.
NCT ID: NCT07225621
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Industry
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to a…
Sponsor: Rigel Pharmaceuticals
NCT ID: NCT06161974
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 2 Recruiting Academic/Other
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05188508
Sites in Pennsylvania: - Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Pennsylvania: - Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
Phase 2 Recruiting Industry
This study will evaluate BCB-276, an investigational B7-H3-targeted Chimeric Antigen Receptor (CAR) T cell therapy, in children and young adults with diffuse intrinsic pontine glioma (DIPG). DIPG is a rare and aggressive brain tumor with l…
Sponsor: BrainChild Bio, Inc
NCT ID: NCT07680439
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
Phase 1, Phase 2 Recruiting Academic/Other
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will …
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05278208
Sites in Pennsylvania: - Children's Hospital of Philadelphia — Philadelphia, Pennsylvania